On June 15, Kelun-Biotech (06990.HK) rose 3.03% in regular trading, trading at HKD 420.6/share, with turnover of approximately HKD 61.39 million.

On the news front, the company disclosed on June 12 that it has received a total of RMB 703 million from Yilian Biopharmaceuticals pursuant to a previously reached settlement agreement. The payment includes RMB 602.5 million in licensing revenue sharing related to the YL201 project. Under the settlement terms, Yilian Bio is obligated to share external licensing revenue and future net sales profits from six ADC drug candidates — YL201, YL202, YL211, YL212, YL221, and YL222 — with Kelun-Biotech. The RMB 703 million represents the initial tranche, with subsequent milestone payments and commercialization royalties expected as the pipeline advances. According to parent company Kelun Pharmaceutical, the amount accounts for 23.30% of its audited net profit attributable to shareholders for the prior fiscal year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)